+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Intraperitoneal (Ip) administration of cisplatin in combination with systemic chemotherapy in patients with malignant ascites of gastrointestinal cancer: clinical evaluation and pharmacokinetics



Intraperitoneal (Ip) administration of cisplatin in combination with systemic chemotherapy in patients with malignant ascites of gastrointestinal cancer: clinical evaluation and pharmacokinetics



Gan No Rinsho. Japan Journal of Cancer Clinics 34(2): 191-195



Ten patients with carcinomatous peritonitis of gastrointestinal cancer have been treated with administrations of CDDP-Ip (50-150 mg/body), in combination with systemic chemotherapy simultaneously combined with sodium thiosulfate (STS) iv in 4 patients. All patients received transfusions of specific hydration. The pharmacokinetics of CDDP was studied in 4 patients, and the following results were obtained. (1) As for its effect on malignant ascites, according to Koyama's and Saito's criteria, 2 patients showed a complete response, 3 showed a partial response, and 5 showed no change. (2) As for its effect on the primary site, only one patient showed a partial response, and the others no change. (2) As to its side effects, 6 patients manifested nausea and vomiting, and only one showed a mild kidney dysfunction, and no myelosuppression. No significant difference in the side effects between the STS-combined group and the non-STS-combined group was found. (3) Serum CDDP levels were reached maximum 1-2 hours after Ip, and gradually decreased during the beta-phase of iv administration. Significant levels of non-protein-bound CDDP were found in the serum within 4 hours after Ip. These results indicate that the CDDP Ip is safe and useful for carcinomatous peritonitis of gastrointestinal cancer, however the combination of STS might weaken the systemic anti-cancer effect of CDDP by neutralizing the non-protein-bound CDDP in the serum.

(PDF emailed within 1 workday: $29.90)

Accession: 040493086

Download citation: RISBibTeXText

PMID: 3126333


Related references

Clinical pharmacokinetics of cisplatin in plasma and ascites fluid for immediate postoperative intraperitoneal administration of cisplatin 5 fluorouracil following surgery for pancreas or colon cancer. Proceedings of the American Association for Cancer Research Annual Meeting 29: 200, 1988

Clinical pharmacology of cisplatin after intraperitoneal administration in patients with malignant ascites. Journal of ChemoTherapy 1(4 Suppl.): 1218-1219, 1989

Clinical efficacy of type-B ultrasound-guided intraperitoneal hyperthermic chemoperfusion combined with systemic chemotherapy in advanced gastric cancer patients with malignant ascites. Neoplasma 63(2): 299-303, 2016

Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. Medical Oncology 32(2): 292, 2015

Intraperitoneal recombinant human endostatin combined with chemotherapy for refractory malignant ascites due to gastrointestinal cancer: a pilot study. Hepato-Gastroenterology 60(121): 118-123, 2013

Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy. Molecular and Clinical Oncology 5(6): 740-744, 2017

Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesothelioma. Lung Cancer 66(2): 269-270, 2010

A pilot study of combination intraperitoneal recombinant human endostatin and chemotherapy for refractory malignant ascites secondary to ovarian cancer. Medical Oncology 31(4): 930, 2014

Clinical study of cis-platinum in the chemotherapy for malignant gastrointestinal disease: arterial infusion and intraperitoneal administration. Gan No Rinsho. Japan Journal of Cancer Clinics 30(10): 1261-1267, 1984

Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Research 22(2b): 1329-1336, 2002

Intraperitoneal infusion of recombinant interleukin-2 in malignant ascites in patients with gastrointestinal and ovarian cancer. Acta Medica Austriaca 16(3-4): 81-83, 1989

Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Research 15(5b): 2201-2206, 1995

Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites. Journal of ChemoTherapy 23(1): 28-31, 2011

Laparoscopic Hyperthermic Intraperitoneal Perfusion Chemotherapy for Patients with Malignant Ascites Secondary to Unresectable Gastric Cancer. Journal of Laparoendoscopic and Advanced Surgical Techniques. Part a 26(1): 32-39, 2016

Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil. Cancer ChemoTherapy and Pharmacology 71(6): 1585-1590, 2013